DT56a stimulates creatine kinase specific activity in vascular tissues of rats.

Journal of Endocrinological Investigation

Volumn 26, Issue 10, 2003, Pages 966-971

  Somjen, Dalia ^a   Yoles, I ^b,c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Aorta; Creatine kinase; Estradiol; Left ventricle of the heart; Phytoestrogens; Raloxifene

Indexed keywords

CREATINE KINASE; DT 56A; ESTRADIOL; ESTROGEN; NATURAL PRODUCT; RALOXIFENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; ESTROGEN ACTIVITY; FEMALE; HEART LEFT VENTRICLE; NONHUMAN; OVARIECTOMY; RAT; RAT STRAIN; SOYBEAN; UTERUS; VASCULAR TISSUE;

EID: 0346368468     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03348193     Document Type: Article

References (41)

1. Kapiotis S, Hermann M, Held I, et al. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler Thromb Vasc Biol 1997, 17: 2868-74.
2. Honore EK, Williams JK, Anthony MS, Clarkson TB. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil Steril 1997, 67: 148-54.
3. Lissin LW, Cooke JP. Phytoestrogens and cardiovascular health. J Am Coll Cardiol 2000, 35: 1403-10.
4. Hodges YK, Tung L, Yan XD, et al. Esterogen receptors alpha and beta: Prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation 2000, 101: 1792-8.
5. Iafrati MD, Karas RH, Aronovitz M, et al. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 1997, 3: 545-8.
6. Somjen D, Knoll E, Kohen F, Stern N. Effects of phytoestrogens on DNA synthesis and creatine kinase activity in vascular cells. Am J Hypertens 2001, 14: 1256-62.
7. Dubey RK, Gillespie DG, Imthurn B, et al. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 1999, 3: 177-82.
8. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139: 4252-63.
9. Enmark E, Gustafsson JA. Oestrogen receptors - An overview. J Intern Med 1999, 246: 133-8.
10. Eng FC, Barsalou A, Akutsu N, et al. Differential classes of coactivators recognize distinct but overlapping binding sites on the estrogen receptor ligand binding domain. J Biol Chem 1998, 273: 28371-7.
11. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulaion of the agonist/antagonist activity of the mixed antiestrogen 4-hydroxy tamoxifen. Mol Endocrinol 1997, 11: 657-66.
12. Phillips DM, Balducci L. Current management of breast cancer. Am Fam Physician 1996, 53: 657-65.
13. Muchmore DB. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist 2000, 5: 388-92.
14. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002, 287: 847-57.
15. Kearney CE, Purdie DW. Selective estrogen receptor modulators. Climacteric 1998, 1: 143-7.
16. Gajdos C, Jordan VC. Selective estrogen receptor modulators as a new therapeutic drug group: Concept to reality in a decade. Clin Breast Cancer 2002, 2: 272-81.
17. Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert Opin Pharmacother 2002, 3: 681-91.
18. Tham DM, Gardner CD, Haskell WL. Potential health benefits of dietary phytoestrogens: A review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 1998, 83: 2223-35.
19. Setchell KDR. Phytoestrogens: The biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998, 68 (Suppl): 1333S-46S.
20. Alkelel DL, St. Germain A, Peterson CT, et al. Isoflavone-rich soy protein isolated attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 2000, 72: 844-9.
21. Ewies AA. Phytoestrogens in the management of the menopause: Up-to-date. Obstet Gynecol Surv 2002, 57: 306-13.
22. Malnick SD, Shaer A, Soreq H, Kaye AM. Estrogen-induced creatine kinase in the reproductive system of the immature female rat. Endocrinology 1983, 113: 1907-9.
23. Somjen D, Weisman Y, Harell A, Berger E, Kaye AM. Direct and sex-specific stimulation by sex steroids by creatine kinase activity and DNA synthesis in rat bone. Proc Natl Acad Sci USA 1989, 86: 3361-5.
24. Somjen D, Waisman A, Kaye AM. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo. J Steroid Biochem Mol Biol 1996, 59: 389-96.
25. Somjen D, Waissman A, Weisman Y, Kaye AM. Nonhypercalcemic analogs of vitamin D stimulate creatine kinase B activity in osteoblast-like ROS 17/2.8 cells and upregulate their responsiveness to estrogens. Steroids 1998, 63: 340-3.
26. Tamir S, Eizenberg M, Somjen D, Izrael S, Vaya J. Estrogen-like activity of glabrene and other constituents isolated from licorice root. J Steroid Biochem Mol Biol 2001, 78: 291-6.
27. Tamir S, Eizenberg M, Somjen D, Izrael S, Vaya J. Estrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells. Cancer Res 2000, 60: 5704-9.
28. Vaya J, Tamir S, Somjen D. Estrogen-like activity of licorice root extract and its constituent. (Submitted to J Steroid Biochem Mol Biol).
29. Wang HJ, Murphy PA. Mass balance study of isoflavones during soybean processing. J Agric Food Chem 1996, 44: 2377-83.
30. Yoles I, Kaplan B, Seidman DS, Chayen B. Phytoestrogens: A time-tested solution for menopausal symptoms revisited. Obstet Gynecol 2002, 99 (Suppl): 58S.
31. Somjen D, Yoles I. DT56a (Tofupill®/Femarelle™) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus. J Steroid Biochem Mol Biol 2003, 86: 93-8
32. Yoles I, Yogev Y, Frenkel Y, Nahum R, Hirsch M, Kaplan B. Tofupill®/Femarelle™ (DT56a) - A new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss. Menopause 2003 (in press).
33. Somjen D, Amir-Zaltsman Y, Gayer B, et al. 6-Carboxymethyl genistein: A novel selective oestrogen receptor modulator (SERM) with unique differential effects on the vasculature, bone and uterus. J Endocrinol 2002, 173: 415-27.
34. Somjen D, Mor Z, Kaye AM. Age dependent and modulation by gonadectomy of the sex specific response of rat diaphyseal bone to gonadal steroids. Endocrinology 1994, 134: 809-14.
35. Liggins J, Grimwood R, Bingham SA. Extraction and quantification of lignan phytoestrogens in food and human samples. Anal Biochem 2000, 287: 102-9.
36. Wiseman H. The therapeutic potential of phytoestrogens. Expert Opin Investig Drugs 2000, 9: 1829-40.
37. Fournier DB, Erdman JW Jr., Gordon GB. Soy, its components and cancer prevention: A review of the in vitro, animal and human data. Cancer Epidemiol Biomarkers Prev 1998; 7: 1055-65.
38. Karas RH, Schulten H, Pare G et al. Effects of estrogen on the vascular injury response in estrogen receptor α, β (double) knockout mice. Circul Res 2001, 89: 534-9.
39. Setchell KD. Soy isoflavones - Benefits and risks from nature's selective estrogen receptor modulators (SERMs). J Am Coll Nutr 2001, 20: 354S-62S and discussion 381S-3S.
40. Barnes S, Boersma B, Patel R, et al. Isoflavonoids and chronic disease: Mechanisms of action. Biofactors 2000, 12: 209-15.
41. Valente M, Buflino L, Castiglione GN, et al. Effects of 1-year treatment with isoipriflavone on bone in post-menopausal women with low bone mass. Calcif Tissue Int 1994, 54: 377-80.